Free Trial

NRx Pharmaceuticals Q1 2023 Earnings Report

NRx Pharmaceuticals logo
$1.57 +0.15 (+10.56%)
(As of 12/24/2024 05:19 PM ET)

NRx Pharmaceuticals EPS Results

Actual EPS
-$13.00
Consensus EPS
-$15.00
Beat/Miss
Beat by +$2.00
One Year Ago EPS
N/A

NRx Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NRx Pharmaceuticals Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

After New Years, price goes back up 4,800% (Ad)

When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!

Click here to review Tim’s special Holiday offer before it’s too late.

NRx Pharmaceuticals Earnings Headlines

Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
NRX Pharmaceuticals Strengthens Leadership with New CFO Appointment
NRx Pharmaceuticals Names Michael Abrams CFO
See More NRx Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NRx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NRx Pharmaceuticals and other key companies, straight to your email.

About NRx Pharmaceuticals

NRx Pharmaceuticals (NASDAQ:NRXP), a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

View NRx Pharmaceuticals Profile

More Earnings Resources from MarketBeat